State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases

MLA

Anne Kasus-Jacobi, and Mark A. Babizhayev. “State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases.” Current Clinical Pharmacology, vol. 4, Jan. 2009, pp. 4–37. EBSCOhost, https://doi.org/10.2174/157488409787236074.

APA

Anne Kasus-Jacobi, & Mark A. Babizhayev. (2009). State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases. Current Clinical Pharmacology, 4, 4–37. https://doi.org/10.2174/157488409787236074

Chicago

Anne Kasus-Jacobi, and Mark A. Babizhayev. 2009. “State of the Art Clinical Efficacy and Safety Evaluation of N-Acetylcarnosine Dipeptide Ophthalmic Prodrug. Principles for the Delivery, Self-Bioactivation, Molecular Targets and Interaction with a Highly Evolved Histidyl-Hydrazide Structure in the Treatment and Therapeutic Management of a Group of Sight-Threatening Eye Diseases.” Current Clinical Pharmacology 4 (January): 4–37. doi:10.2174/157488409787236074.